Neuralink is an emerging startup founded by Elon Musk that has made headlines around the world. This medical device company is focused on brain-computer interface technology, which holds immense potential for applications in the field of neurotechnology. According to recent research conducted by Forbes, the neurotech market is projected to reach an impressive $16.8 billion by 2026.
Although Neuralink remains a private company, there are strategic ways to take advantage of its cutting-edge technology. In this article, we will guide you through various methods to invest in Neuralink and provide insight into the company’s operations and business model so you can make informed decisions about your investment portfolio.
Neuralink: Company Overview
Neuralink was established in 2016 by Elon Musk and a team of elite neuroscientists. Headquartered in California, the company aims to revolutionize the way humans and computers interact through highly sophisticated brain implants. Neuralink has received FDA clearance for human trials in 2023 and plans to begin commercialization in 2024. These developments signify a pivotal leap towards implementing their technology in medical applications.
Updates on Neuralink’s Human Trials:
In a safety trial for a brain-computer interface called the Link, a malfunction was reported on May 8th, 2024 in a brain implant used on a human patient. The implant, which was made up of 1,024 electrodes across 64 ultra-fine threads, was implanted in a 29-year-old patient named Noland Arbaugh. Following the implantation, some of the threads retracted, which reduced the number of functional electrodes and impacted the performance measurements.
However, Neuralink was able to adjust its software and techniques without needing to remove the implant as it posed no immediate safety risk. Mr. Arbaugh continues to use the system extensively and finds it helpful for reconnecting with the world, describing it as providing a “luxury overload.” Nevertheless, Neuralink needs to undergo further safety and efficacy testing before seeking FDA approval, which is a crucial step towards broader application of their technology.
Ready to make informed investment decisions? Watch our in-depth analysis Video on Neuralink!
How to Buy Neuralink Stock?
Currently, Neuralink is a private company and has not publicly announced any plans to IPO in the near future. Therefore, buying Neuralink stock directly is not an option for the general public or retail investors. Only accredited investors can invest in Neuralink through the Hiive platform.
Read More: How to Buy Waymo Stock?
Invest in Neuralink’s Investors and Partners:
You can indirectly invest in Neuralink through different alternatives, even though most people can’t afford to invest directly in the company. One such option is to invest in companies that have invested and partnered with Neuralink.
1. Tesla:
Tesla Inc. (TSLA: NSD) has not only been at the forefront of revolutionizing the electric vehicle industry but has also shown significant interest in the potential of Neuralink. Elon Musk, who is also the founder of Neuralink, has a deep personal and financial commitment to the success of the company. As a result, by investing in Tesla, one can indirectly align with Musk’s vision for Neuralink’s success.
2. Google:
Google Ventures, the venture capital investment arm of Alphabet Inc. (GOOG: NSD), has made substantial investments in Neuralink. With Google Ventures backing the development of Neuralink, investors can explore the option of indirectly supporting Neuralink’s vision by investing in Alphabet (Google’s parent company). This strategic investment in neural technology positions Google as a key player in the evolving field of brain-computer interfaces. Thus, by considering an investment in Google, one can indirectly benefit from the potential success of Neuralink and the advancements in brain-machine interface technology.
How does Neuralink Generate Revenue?
Neuralink currently generates revenue through speculative means, as the company is in the developmental and trial phase. However, its main revenue is expected to come from the commercialization of its innovative brain implants, which have the potential to treat neurological disorders and enhance human cognitive capabilities.
This advanced neurotechnology could lead to diverse applications in the medical sciences and beyond, positioning Neuralink as a lucrative business. Additionally, the company may explore partnerships and the commercialization of its brain-computer interface technology in the future, further expanding its revenue potential.
Key Competitors of Neuralink:
Neuralink faces tough competition in the brain-computer interface (BCI) industry from significant players. One of its formidable competitors is Intuitive Surgical, known for its leadership in robotic-assisted surgeries and advancements in areas that intersect with Neuralink’s objectives.
1. Intuitive Surgical (ISRG: NSD):
A leader in robotic-assisted surgeries, Intuitive Surgical poses a significant challenge to Neuralink. The company’s expertise in this field, coupled with its innovative advancements, makes it a worthy competitor. However, Neuralink maintains a unique advantage with its high-profile backing and advanced technological propositions, setting it apart in this competitive landscape.
Conclusion:
While buying stock directly in Neuralink is not currently possible, the company’s ongoing developments and the excitement surrounding its future potential make it an attractive subject for investor attention. By investing in associated companies or staying updated on Neuralink’s progress toward an IPO, investors can prepare to participate in what could be a groundbreaking venture in the intersection of technology and human health.
Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product/services forecast as indicated by major brokers covering the stock.
